Published in J Natl Cancer Inst on October 20, 2016
Weight change, obesity, and risk of prostate cancer progression among men with clinically localized prostate cancer. Int J Cancer (2017) 0.75
Adiposity across the adult life course and incidence of primary liver cancer: The NIH-AARP cohort. Int J Cancer (2017) 0.75
Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC Med (2017) 0.75
Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA (2012) 33.54
Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ (1987) 27.11
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
A comparison of direct vs. self-report measures for assessing height, weight and body mass index: a systematic review. Obes Rev (2007) 14.60
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Validity of self-reported waist and hip circumferences in men and women. Epidemiology (1990) 10.57
Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol (1997) 9.25
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr (2002) 7.01
A note on the analysis of repeated measurements of the same subjects. J Chronic Dis (1962) 6.18
The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med (2012) 5.63
When is baseline adjustment useful in analyses of change? An example with education and cognitive change. Am J Epidemiol (2005) 4.54
Overweight, obesity, and cancer risk. Lancet Oncol (2002) 4.44
Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol (2010) 4.07
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med (2011) 3.77
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology (2007) 3.60
Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 3.29
Changes in the distribution of body mass index of adults and children in the US population. Int J Obes Relat Metab Disord (2000) 3.04
The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol (1993) 2.95
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem (2008) 2.40
Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer (2007) 2.29
Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control (2006) 2.29
Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2011) 2.19
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev (2007) 1.97
Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer (2009) 1.90
Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.77
Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst (2003) 1.65
Insulin resistance and prostate cancer risk. J Natl Cancer Inst (2003) 1.61
Mathematical coupling: a multilevel approach. Int J Epidemiol (2004) 1.43
Obesity and mortality risk: new findings from body mass index trajectories. Am J Epidemiol (2013) 1.42
Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer (2015) 1.32
Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst (2009) 1.27
Agreement between self-reported and measured height, weight and body mass index in old age--a longitudinal study with 20 years of follow-up. Age Ageing (2010) 1.23
Early life risk factors for prostate cancer: a population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev (1995) 1.20
Prostate cancer: is it time to expand the research focus to early-life exposures? Nat Rev Cancer (2013) 1.08
Weight change and prostate cancer incidence and mortality. Int J Cancer (2012) 1.03
Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst (2015) 1.01
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-α and GPER signalling. Mol Cell Endocrinol (2012) 1.00
Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer. World J Urol (2012) 0.94
Accuracy of recalled body weight--a study with 20-years of follow-up. Obesity (Silver Spring) (2013) 0.93
Trajectory of body shape across the lifespan and cancer risk. Int J Cancer (2016) 0.93
Systematic review of prostate cancer's association with body size in childhood and young adulthood. Cancer Causes Control (2008) 0.91
On the bias caused by regression toward the mean in studying the relation between change and initial value. J Clin Periodontol (1987) 0.90
The problem of analysing the relationship between change and initial value in oral health research. Eur J Oral Sci (2005) 0.89
Relationship of body mass, height, and weight gain to prostate cancer risk in the multiethnic cohort. Cancer Epidemiol Biomarkers Prev (2009) 0.88
Obesity before age 30 years and risk of advanced prostate cancer. Am J Epidemiol (2005) 0.85
Commentary: methods for analysing life course influences on health--untangling complex exposures. Int J Epidemiol (2011) 0.83
Lifetime body size and prostate cancer risk in a population-based case-control study in Sweden. Cancer Causes Control (2013) 0.82
Body size across the life course and prostate cancer in the Health Professionals Follow-up Study. Int J Cancer (2015) 0.80
Adult weight gain and risk of prostate cancer: A dose-response meta-analysis of observational studies. Int J Cancer (2015) 0.76
Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis. Prostate Cancer Prostatic Dis (2016) 0.76
Trends in the Incidence of Fatal Prostate Cancer in the United States by Race. Eur Urol (2016) 0.77